GeNeuro SA (EPA:GNRO)

France flag France · Delayed Price · Currency is EUR
0.0692
0.00 (0.00%)
May 15, 2025, 5:06 PM CET
-95.45%
Market Cap 2.05M
Revenue (ttm) n/a
Net Income (ttm) -14.76M
Shares Out 29.60M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,836
Average Volume 45,066
Open 0.0740
Previous Close 0.0692
Day's Range 0.0692 - 0.0740
52-Week Range 0.0428 - 2.3500
Beta 0.75
RSI 47.95
Earnings Date May 2, 2025

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 17
Stock Exchange Euronext Paris
Ticker Symbol GNRO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.